World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0003467900
Reproduction Date:

Title: Abacavir/lamivudine/zidovudine  
Author: World Heritage Encyclopedia
Language: English
Subject: Lamivudine/zidovudine, Smith, Kline & French, Solpadeine, Antiretroviral drugs, Antiretroviral drug
Publisher: World Heritage Encyclopedia


Combination of
Abacavir Nucleotide analogue reverse transcriptase inhibitor
Lamivudine Nucleoside analogue reverse transcriptase inhibitor
Zidovudine Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names Trizivir
  • US: C (Risk not ruled out)
Legal status
Routes of
CAS Registry Number  N
ATC code J05
ChemSpider  Y

Abacavir/lamivudine/zidovudine (INNs, trade name Trizivir) is a pharmaceutical treatment for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and now marketed by its joint venture with Pfizer, ViiV Healthcare:[2]

It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]

The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

In December 2013, Lupin Limited launched a generic version of Trizivir. [5][6]

See Also


  1. ^ Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases 185 (9): 1251–1260.  
  2. ^ GlaxoSmithKline-Pfizer launch HIV joint venture
  3. ^ Trizivir
  4. ^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV" (1). pp. CD006734.  
  5. ^ Monthly Prescribing Reference (MPR): [3]
  6. ^ Lupin Pharma: [4]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.